ClinicalTrials.gg
CompletedNCT04994912Updated Jun 24, 2025

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

A Phase 1 interventional study of EI-001 and Placebo in Healthy, sponsored by Elixiron Immunotherapeutics (Hong Kong) Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Elixiron Immunotherapeutics (Hong Kong) Ltd. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A First-in-Human, Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-001 in Healthy Volunteers.

Read the detailed description

To assess the safety and tolerability of single ascending intravenous (IV) doses of EI-001 in healthy volunteers

To assess the pharmacokinetics (PK) of single ascending IV doses of EI-001 in healthy volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Elixiron Immunotherapeutics (Hong Kong) Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female 18 to ≤ 55 years old at the time of consent.
  2. Healthy on the basis of physical examination, medical history, vital signs, laboratory values and 12-lead performed at Screening. The participant may be included only if the investigator judges any abnormalities or deviations from normal to be not .

Exclusion criteria

Exclusion Criteria:

  1. Prior or ongoing medical conditions, medical history, physical findings, or laboratory abnormality that, in the Investigator's (or delegate's) opinion, may require treatment or render the participant unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures or interfere with study assessments.
  2. Have received any IP within 30 days or 5 half-lives prior to Screening (4 months if the previous drug was a new chemical entity), whichever is longer.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    EI-001

    IV infusion

    Drug: EI-001

  • Placebo comparator
    Placebo

    IV infusion

    Other: Placebo

Interventions

  • DrugEI-001

    EI-001 IV infusion

  • OtherPlacebo

    Placebo IV infusion

06

What researchers measure

Primary outcomes

  1. safety assessment

    to assess blood pressure

    Time frame: Day 1

  2. safety assessment

    to assess heart rate

    Time frame: Day 1

  3. safety assessment

    to assess respiratory rate

    Time frame: Day 1

Secondary outcomes

  1. PK assessment

    To assess Maximum observed concentration (Cmax)

    Time frame: Day 1

  2. PK assessment

    To assess time to maximum observed drug concentration (Tmax)

    Time frame: Day 1

  3. PK assessment

    to assess AUC from time zero to the last measurable concentration (AUC0-t)

    Time frame: Day 1

07

Study locations

2 sites
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
  • Huashan Hospital of Fudan University
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jan 2025, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Aug 6, 2021
StartActual
Oct 1, 2021
Primary completionActual
Jan 7, 2025
CompletionActual
Feb 18, 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994912
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Oct 1, 2021
Primary completion
Jan 7, 2025
Completion
Feb 18, 2025
Last update
Jun 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Start the discussion